NCT00857571 - A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Healthy

Interventions

DRUG

150 mg Suspension

Single oral dose of 150 mg of PF-02413873 suspension

DRUG

30 mg Suspension

Single oral dose of 30 mg of PF-02413873 suspension

DRUG

400 mg Suspension

Single oral dose of 400 mg of PF-02413873 suspension

DRUG

5 mg Suspension

Single oral dose of 5 mg of PF-02413873 suspension

DRUG

750 mg Suspension

Single oral dose of 750 mg of PF-02413873 suspension

DRUG

150 mg Tablet

Single oral dose of 150 mg of PF-02413873 tablets

DRUG

30 mg Tablet

Single oral dose of 30 mg of PF-02413873 tablets

DRUG

400 mg Tablet

Single oral dose of 400 mg of PF-02413873 tablets

DRUG

5 mg Tablet

Single oral dose of 5 mg of PF-02413873 tablets

DRUG

750 mg Tablet

Single oral dose of 750 mg of PF-02413873 tablets

Trial Locations (1)

Pfizer Investigational Site, Singapore